ENTA (Enanta Pharmaceuticals) Cyclically Adjusted FCF per Share: $-1.33 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ENTA Enanta Pharmaceuticals Inc ENTA
49 GF Score
Price $14.08
GF Value $7.93
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals Cyclically Adjusted FCF per Share?

Enanta Pharmaceuticals ENTA -0.14% 49 Cyclically Adjusted FCF per Share is $-1.33 as of Jun. 2026. GuruFocus rates ENTA with a GF Score™ of 49/100 and a GF Value™ of $7.93 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Enanta Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was $-0.343. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.33 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-26), Enanta Pharmaceuticals's current stock price is $14.08. Enanta Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-1.33. Enanta Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Enanta Pharmaceuticals was 127.00. The lowest was 13.62. And the median was 30.75.


Enanta Pharmaceuticals  (NAS:ENTA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Enanta Pharmaceuticals was 127.00. The lowest was 13.62. And the median was 30.75.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Enanta Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Enanta Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.17 1.78 0.32 -0.26 -0.96

Enanta Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.94 -0.96 -1.20 -1.31 -1.33

ENTA vs CMPX, CCCC, LXEO: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


ENTA
49GF Score
Enanta Pharmaceuticals Inc ENTA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enanta Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.343/333.9520*333.9520
=-0.343

Current CPI (Jun. 2026) = 333.9520.

Enanta Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.132 241.428 -0.183
201612 0.115 241.432 0.159
201703 -0.188 243.801 -0.258
201706 -0.290 244.955 -0.395
201709 2.789 246.819 3.774
201712 0.196 246.524 0.266
201803 -0.404 249.554 -0.541
201806 0.140 251.989 0.186
201809 1.315 252.439 1.740
201812 1.435 251.233 1.907
201903 1.308 254.202 1.718
201906 0.014 256.143 0.018
201909 0.395 256.759 0.514
201912 0.572 256.974 0.743
202003 0.719 258.115 0.930
202006 -0.238 257.797 -0.308
202009 -0.787 260.280 -1.010
202012 -0.750 260.474 -0.962
202103 -0.233 264.877 -0.294
202106 -1.480 271.696 -1.819
202109 -1.041 274.310 -1.267
202112 -0.669 278.802 -0.801
202203 -1.287 287.504 -1.495
202206 -1.441 296.311 -1.624
202209 -0.818 296.808 -0.920
202212 -1.864 296.797 -2.097
202303 -0.769 301.836 -0.851
202306 -1.628 305.109 -1.782
202309 -1.091 307.789 -1.184
202312 -1.222 306.746 -1.330
202403 -1.430 312.332 -1.529
202406 -1.006 314.175 -1.069
202409 -0.913 315.301 -0.967
202412 -1.203 315.605 -1.273
202503 -0.750 319.799 -0.783
202506 0.812 322.561 0.841
202509 -0.372 324.800 -0.382
202512 -0.412 324.054 -0.425
202603 -0.247 330.213 -0.250
202606 -0.343 333.952 -0.343

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-1.33 mean?
Enanta Pharmaceuticals (ENTA) has a Cyclically Adjusted FCF per Share of $-1.33 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Enanta Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-1.33. Overall, Enanta Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' Cyclically Adjusted FCF per Share compare to CMPX and CCCC?
Enanta Pharmaceuticals' Cyclically Adjusted FCF per Share of $-1.33 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-1.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (ENTA) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.93, compared to a current price of $14.08 — trading 77.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-1.33. Enanta Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Enanta Pharmaceuticals (ENTA), the current Cyclically Adjusted FCF per Share is $-1.33 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (ENTA) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of $14.08 is trading 77.6% above its estimated GF Value™ of $7.93. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ENTA:

  • Cyclically Adjusted FCF per Share: $-1.33
  • GF Value™: $7.93 vs. price of $14.08 (77.6% above fair value)
  • GF Score™: 49/100 with 7 warning signs

No single metric tells the full story. See the ENTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enanta Pharmaceuticals Business Description

Other Exchanges 9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
49GF Score

Get the complete analysis for ENTA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.08
Price
$7.93
GF Value